GlassScriptPhysician profile
Younchan Lee
NPI 1609223726
$2,075.70
in general payments reported to CMS, 2019-2025
16 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $514 · 2023: $442 · 2024: $314 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.68 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $226.96 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $205.04 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $174.32 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.94 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $131.73 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $109.03 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $85.68 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $52.27 | 2024-2025 | Auvelity |
| Indivior INC. | $48.71 | 2022-2023 | Perseris |
| Janssen Pharmaceuticals, INC | $36.00 | 2022-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $32.55 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.48 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $21.29 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2025 | Cobenfy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $13.91 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Younchan Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.